Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC

[1]  I. Ulasov,et al.  Emerging principles of brain immunology and immune checkpoint blockade in brain metastases. , 2021, Brain : a journal of neurology.

[2]  J. Galon,et al.  The immune contexture and Immunoscore in cancer prognosis and therapeutic efficacy , 2020, Nature Reviews Cancer.

[3]  C. Brennan,et al.  Interrogation of the Microenvironmental Landscape in Brain Tumors Reveals Disease-Specific Alterations of Immune Cells , 2020, Cell.

[4]  B. Becher,et al.  Single-Cell Mapping of Human Brain Cancer Reveals Tumor-Specific Instruction of Tissue-Invading Leukocytes , 2020, Cell.

[5]  T. Isobe,et al.  Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells , 2020, Cancer science.

[6]  N. Hanna,et al.  Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Jeffrey E. Lee,et al.  B cells and tertiary lymphoid structures promote immunotherapy response , 2020, Nature.

[8]  Yanhui Liu,et al.  Use of Programmed Death Receptor-1 and/or Programmed Death Ligand 1 Inhibitors for the Treatment of Brain Metastasis of Lung Cancer , 2020, OncoTargets and therapy.

[9]  E. Sato,et al.  Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports , 2019, BMC Cancer.

[10]  Yong Gu,et al.  PD-1 Expression and Function of T-Cell Subsets in TILs From Human Lung Cancer , 2019, Journal of immunotherapy.

[11]  L. Hansen,et al.  Stereotactic Radiosurgery With and Without Checkpoint Inhibition for Patients with Metastatic Non-Small Cell Lung Cancer to the Brain: A Matched Cohort Study , 2019, Neurosurgery.

[12]  J. Huse,et al.  Suppressed immune microenvironment and repertoire in brain metastases from patients with resected non-small-cell lung cancer. , 2019 .

[13]  M. Harada,et al.  Different sensitivities of senescent breast cancer cells to immune cell‐mediated cytotoxicity , 2019, Cancer science.

[14]  T. Yamanaka,et al.  The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV , 2019, International Journal of Clinical Oncology.

[15]  Joe Y. Chang,et al.  Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment , 2019, Front. Immunol..

[16]  H. Nishikawa,et al.  Regulatory T cells in cancer immunosuppression — implications for anticancer therapy , 2019, Nature Reviews Clinical Oncology.

[17]  John T. Poirier,et al.  NK cell–mediated cytotoxicity contributes to tumor control by a cytostatic drug combination , 2018, Science.

[18]  Yi-long Wu,et al.  Stromal PD‐L1–Positive Regulatory T cells and PD‐1–Positive CD8‐Positive T cells Define the Response of Different Subsets of Non–Small Cell Lung Cancer to PD‐1/PD‐L1 Blockade Immunotherapy , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[19]  C. Bettegowda,et al.  Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. , 2017, International journal of radiation oncology, biology, physics.

[20]  T. Isomura,et al.  Diagnostic significance of intratumoral CD8+ tumor-infiltrating lymphocytes in medullary carcinoma. , 2017, Human pathology.

[21]  H. Iwata,et al.  Comparison of immune microenvironments between primary tumors and brain metastases in patients with breast cancer , 2017, Oncotarget.

[22]  F. Aversa,et al.  Low PD-1 Expression in Cytotoxic CD8+ Tumor-Infiltrating Lymphocytes Confers an Immune-Privileged Tissue Microenvironment in NSCLC with a Prognostic and Predictive Value , 2017, Clinical Cancer Research.

[23]  Betty Y. S. Kim,et al.  Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[24]  K. Patel,et al.  Ipilimumab and Stereotactic Radiosurgery Versus Stereotactic Radiosurgery Alone for Newly Diagnosed Melanoma Brain Metastases , 2017, American journal of clinical oncology.

[25]  M. Socinski,et al.  First‐Line Nivolumab in Stage IV or Recurrent Non–Small‐Cell Lung Cancer , 2017, The New England journal of medicine.

[26]  Young A Kim,et al.  Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. , 2017, European journal of cancer.

[27]  Ralph R. Weichselbaum,et al.  Radiotherapy and immunotherapy: a beneficial liaison? , 2017, Nature Reviews Clinical Oncology.

[28]  Betty Y. S. Kim,et al.  Immune Priming of the Tumor Microenvironment by Radiation. , 2016, Trends in cancer.

[29]  L. Zitvogel,et al.  Immunogenic cell death in cancer and infectious disease , 2016, Nature Reviews Immunology.

[30]  Y. Shentu,et al.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.

[31]  Gwénaël Le Teuff,et al.  Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  H. Nishikawa,et al.  Roles of regulatory T cells in cancer immunity. , 2016, International immunology.

[33]  J. Stebbing,et al.  Intra-tumoral heterogeneity in the expression of programmed-death (PD) ligands in isogeneic primary and metastatic lung cancer: Implications for immunotherapy , 2016, Oncoimmunology.

[34]  Xiaozhen Liu,et al.  Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis , 2016, Oncotarget.

[35]  M. Hattori,et al.  Two FOXP3+CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers , 2016, Nature Medicine.

[36]  Chuan-miao Xie,et al.  Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer , 2016, Oncotarget.

[37]  H. Heinzl,et al.  Density of tumor-infiltrating lymphocytes correlates with extent of brain edema and overall survival time in patients with brain metastases , 2016, Oncoimmunology.

[38]  Bernard A. Fox,et al.  Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma , 2015, Journal of Immunotherapy for Cancer.

[39]  L. Crinò,et al.  Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.

[40]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[41]  H. Ditzel,et al.  Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.

[42]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[43]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[44]  P. Ellis,et al.  Brain metastases in non-small-cell lung cancer. , 2014, Clinical lung cancer.

[45]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[46]  J. Kuratsu,et al.  Possible involvement of the M2 anti‐inflammatory macrophage phenotype in growth of human gliomas , 2008, The Journal of pathology.

[47]  T. Dønnem,et al.  Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer , 2008, Clinical Cancer Research.

[48]  A. Young,et al.  Treatment for patients with cerebral metastases. , 1978, Archives of neurology.

[49]  F. Jamali,et al.  Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.